3,5-Dijodotironin

3,5-Dijodotironin
Nazivi
	IUPAC naziv 2-Amino-3-[4-(4-hidroksifenoksi)-3,5-dijodofenil]propanoinska kiselina
Identifikacija
3D model (Jmol)	interaktivna slika; interaktivna slika;
ChemSpider	110252 ;
MeSH	3,5-diiodothyronine
PubChem C ID	123675;
	SMILES C1=CC(=CC=C1O)OC2=C(C=C(C=C2I)CC(C(=O)O)N)I; C1=CC(=CC=C1O)OC2=C(C=C(C=C2I)CC(C(=O)O)N)I; ; ; ; ;
Svojstva
Hemijska formula	C15H13I2NO4
Molarna masa	525,077 g/mol
	Ukoliko nije drugačije napomenuto, podaci se odnose na standardno stanje materijala (na 25 °C [77 °F], 100 kPa).
	Reference infokutije

3,5-Dijodotironin (3,5-T₂) je aktivni tiroidni hormon iz klase jodotironina. Ovaj moleku sadrži dva atoma joda u pozicijama 3 i 5 unutrašnjeg prstena.

Biološko dejstvo уреди

3,5-T2 je aktivan tiroidni hormon. On stimuliše TR-beta receptor tiroidnih hormona i time povišava utrošak energije.^[3]^[4] In vrši agonistički (tiromimetički) uticaj na miokardijsko tkivo i hipofizu, što dovodi do supresije TSH oslobađanja.^[5]^[6] 3,5-T2 je alosterni regulator citohrom c oksidaze, kompleksa IV lanca transporta elektrona. Dolazi do povećanja aktivnosti putem prevencije interakcije adenozin trifosfata (ATP) kao alosternog inhibitora.^[7]

Klinički značaj уреди

Kod obolelih od netireoidne bolesti su 3,5-T2 koncentracije povećane.^[8]^[9] To može da objasni zašto na pacijente sa sindromom niskog T3 supstituciona terapija tiroidnim hormonom nema uticaja.^[8]

Reference уреди

^ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today. 15 (23-24): 1052—7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003. уреди
^ Evan E. Bolton; Yanli Wang; Paul A. Thiessen; Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry. 4: 217—241. doi:10.1016/S1574-1400(08)00012-1.
^ Goglia F (2014). „The effects of 3,5-diiodothyronine on energy balance”. Frontiers in Physiology. 5: 528. PMID 25628573. doi:10.3389/fphys.2014.00528.
^ Lombardi A, Senese R, De Matteis R, Busiello RA, Cioffi F, Goglia F, Lanni A (2015). „3,5-Diiodo-L-thyronine activates brown adipose tissue thermogenesis in hypothyroid rats”. PLOS ONE. 10 (2): e0116498. PMC 4319745  . PMID 25658324. doi:10.1371/journal.pone.0116498.
^ Padron AS, Neto RA, Pantaleão TU, de Souza dos Santos MC, Araujo RL, de Andrade BM, da Silva Leandro M, de Castro JP, Ferreira AC, de Carvalho DP (2014). „Administration of 3,5-diiodothyronine (3,5-T2) causes central hypothyroidism and stimulates thyroid-sensitive tissues”. The Journal of Endocrinology. 221 (3): 415—27. PMID 24692290. doi:10.1530/JOE-13-0502.
^ Jonas W, Lietzow J, Wohlgemuth F, Hoefig CS, Wiedmer P, Schweizer U, Köhrle J, Schürmann A (2015). „3,5-Diiodo-L-thyronine (3,5-t2) exerts thyromimetic effects on hypothalamus-pituitary-thyroid axis, body composition, and energy metabolism in male diet-induced obese mice”. Endocrinology. 156 (1): 389—99. PMID 25322465. doi:10.1210/en.2014-1604.
^ Arnold S.; Goglia F.; Kadenbach B. (1998). „3,5-Diiodothyronine binds to subunit Va of cytochrome-c oxidase and abolishes the allosteric inhibition of respiration by ATP.”. Eur J Biochem. 252 (2): 325—330. PMID 9523704. doi:10.1046/j.1432-1327.1998.2520325.x.
^ ^а ^б Dietrich JW, Müller P, Schiedat F, Schlömicher M, Strauch J, Chatzitomaris A, Klein HH, Mügge A, Köhrle J, Rijntjes E, Lehmphul I (2015). „Nonthyroidal Illness Syndrome in Cardiac Illness Involves Elevated Concentrations of 3,5-Diiodothyronine and Correlates with Atrial Remodeling”. European Thyroid Journal. 4 (2): 129—37. PMC 4521060  . PMID 26279999. doi:10.1159/000381543.
^ Pinna G, Meinhold H, Hiedra L, Thoma R, Hoell T, Gräf KJ, Stoltenburg-Didinger G, Eravci M, Prengel H, Brödel O, Finke R, Baumgartner A (1997). „Elevated 3,5-diiodothyronine concentrations in the sera of patients with nonthyroidal illnesses and brain tumors”. The Journal of Clinical Endocrinology and Metabolism. 82 (5): 1535—42. PMID 9141546. doi:10.1210/jcem.82.5.3939.

Spoljašnje veze уреди

3,5-diiodothyronine на US National Library of Medicine Medical Subject Headings (MeSH)

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today. 15 (23-24): 1052—7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003. уреди

[2] Evan E. Bolton; Yanli Wang; Paul A. Thiessen; Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry. 4: 217—241. doi:10.1016/S1574-1400(08)00012-1.

[3] Goglia F (2014). „The effects of 3,5-diiodothyronine on energy balance”. Frontiers in Physiology. 5: 528. PMID 25628573. doi:10.3389/fphys.2014.00528.

[4] Lombardi A, Senese R, De Matteis R, Busiello RA, Cioffi F, Goglia F, Lanni A (2015). „3,5-Diiodo-L-thyronine activates brown adipose tissue thermogenesis in hypothyroid rats”. PLOS ONE. 10 (2): e0116498. PMC 4319745  . PMID 25658324. doi:10.1371/journal.pone.0116498.

[5] Padron AS, Neto RA, Pantaleão TU, de Souza dos Santos MC, Araujo RL, de Andrade BM, da Silva Leandro M, de Castro JP, Ferreira AC, de Carvalho DP (2014). „Administration of 3,5-diiodothyronine (3,5-T2) causes central hypothyroidism and stimulates thyroid-sensitive tissues”. The Journal of Endocrinology. 221 (3): 415—27. PMID 24692290. doi:10.1530/JOE-13-0502.

[6] Jonas W, Lietzow J, Wohlgemuth F, Hoefig CS, Wiedmer P, Schweizer U, Köhrle J, Schürmann A (2015). „3,5-Diiodo-L-thyronine (3,5-t2) exerts thyromimetic effects on hypothalamus-pituitary-thyroid axis, body composition, and energy metabolism in male diet-induced obese mice”. Endocrinology. 156 (1): 389—99. PMID 25322465. doi:10.1210/en.2014-1604.

[7] Arnold S.; Goglia F.; Kadenbach B. (1998). „3,5-Diiodothyronine binds to subunit Va of cytochrome-c oxidase and abolishes the allosteric inhibition of respiration by ATP.”. Eur J Biochem. 252 (2): 325—330. PMID 9523704. doi:10.1046/j.1432-1327.1998.2520325.x.

[dietrich2015-8] а ^б Dietrich JW, Müller P, Schiedat F, Schlömicher M, Strauch J, Chatzitomaris A, Klein HH, Mügge A, Köhrle J, Rijntjes E, Lehmphul I (2015). „Nonthyroidal Illness Syndrome in Cardiac Illness Involves Elevated Concentrations of 3,5-Diiodothyronine and Correlates with Atrial Remodeling”. European Thyroid Journal. 4 (2): 129—37. PMC 4521060  . PMID 26279999. doi:10.1159/000381543.

[9] Pinna G, Meinhold H, Hiedra L, Thoma R, Hoell T, Gräf KJ, Stoltenburg-Didinger G, Eravci M, Prengel H, Brödel O, Finke R, Baumgartner A (1997). „Elevated 3,5-diiodothyronine concentrations in the sera of patients with nonthyroidal illnesses and brain tumors”. The Journal of Clinical Endocrinology and Metabolism. 82 (5): 1535—42. PMID 9141546. doi:10.1210/jcem.82.5.3939.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]